Sophia Koleczko
Koeln, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
Journal: ESMO open
Published: August 15, 2023
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 28, 2022
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.
Journal: NPJ precision oncology
Published: February 25, 2021
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: September 30, 2020
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 21, 2020
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 17, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 12, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026